MPLA (PHAD™) A80030 (Previously 699800) Monophosphoryl Lipid A (Synthetic) (PHAD™)
Vaccination is well-accepted as an effective method to prevent infections by mounting pathogen-specific immune responses prior to the infection. Usually, immunization with vaccine antigens alone is not able to induce robust or long-lasting immune responses — resulting in failure of protective immunity against infections. Thus, adjuvants are required to enhance cellular or humoral immune responses upon immunization. Because vaccine adjuvants using Lipid A have proven to be safe and effective in inducing Th-1 type immune responses to heterologous proteins in animal and human vaccines, Avanti developed Phosphorylated HexaAcyl Disaccharide (PHAD™), the first fully synthetic monophosphoryl Lipid A available for use as an adjuvant in human vaccines.
PHAD™ is a synthetic structural analog of monophosphoryl Lipid A (MPLA) that has been shown to boost the immune system through activation of the toll-like receptor 4 (TLR4) resulting in production of proinflammatory cytokines and antigen-specific effector CD4+ and memory CD8+ T cells. Also referred to as GLA, this adjuvant has been administered to well over 1000 human subjects without serious adverse events. PHAD™ is available in bulk quantities for vaccine development and commercial manufacturing.
Stimulatory effect of PHAD™, 3D-PHAD™, and 3D(6-acyl)-PHAD™ on macrophages. Macrophage cell line J774 cells were cultured with Avanti PHAD™, 3D-PHAD™, or 3D(6-acyl)-PHAD™ for 24hrs. IL-12 levels in supernatants were measured by sandwich ELISA.
